Oral fluoropyrimidine-induced severe hyperlipidemia


Creative Commons License

Yıldız B. , Kavgacı H., Fidan E., Güngör E., Ersöz H. Ö. , Özdemir F., ...More

ASIAN BIOMEDICINE, vol.4, no.4, pp.627-630, 2010 (Journal Indexed in SCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 4 Issue: 4
  • Publication Date: 2010
  • Doi Number: 10.2478/abm-2010-0079
  • Title of Journal : ASIAN BIOMEDICINE
  • Page Numbers: pp.627-630
  • Keywords: Adverse event, capecitabine, hypertriglyceridemia, oral fluoropyrimidine, UFT (R) drug, METASTATIC COLORECTAL-CANCER, HYPERTRIGLYCERIDEMIA, FLUOROURACIL, LEUCOVORIN

Abstract

Background: Severe hyperlipidemia secondary to capecitabine, an oral fluoropyrimidine, is a very rare condition. There are no reported cases of hyperlipidemia associated with Uracil/tegafur (U FT).